AstraZeneca India Stock: Cancer Drug ko mili approval, Share mein aayi tezi!

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAnanya Iyer|Published at:
AstraZeneca India Stock: Cancer Drug ko mili approval, Share mein aayi tezi!
Overview

AstraZeneca Pharma India ke liye ekdum badhiya news hai! Inki gastric cancer wali dawa, Imfinzi (durvalumab), ko CDSCO se finally approval mil gaya hai. Ab yeh India mein bik sakegi.

CDSCO ne di Imfinzi ko green signal!

Basically, AstraZeneca Pharma India ko unki new immunotherapy drug Imfinzi (durvalumab) ke liye India mein Central Drugs Standard Control Organisation (CDSCO) se approval mil gaya hai. Yeh drug specially resectable gastric ya gastroesophageal junction adenocarcinoma wale adult patients ke liye hai, jab woh FLOT chemotherapy ke saath use hogi. Is approval se India mein advanced cancer treatments ke liye aur bhi options khul gaye hain.

Kya hai Imfinzi ka magic?

Yeh approval tab aaya hai jab drug ko standard FLOT chemotherapy ke saath combine karke use kiya jayega. Yeh surgery se pehle (neoadjuvant) aur surgery ke baad (adjuvant) dono tarah se kaam karegi. MATTERHORN Phase III trial ke results kaafi zabardast rahe hain; isse death ka risk 22% tak kam hua hai, aur 69% log teen saal baad bhi zinda the, jo sirf chemotherapy wale 62% se kaafi zyada hai. Ab yeh drug India mein bechi ja sakti hai, bas kuch aur formalities baaki hain.

Market ka reaction?

Yeh khabar sunte hi stock market ne bhi positive response dikhaya. Pichle trading session mein AstraZeneca Pharma India ka share 1.8% badh kar ₹8,550 par close hua. Pura saal dekha jaaye toh stock 18% upar gaya hai, jisse investors ka bharosa dikh raha hai.

Company ki financial health kaisi hai?

AstraZeneca India ka market cap lagbhag ₹21,000 crore hai. Haalanki, inka Price-to-Earnings (P/E) ratio thoda high, lagbhag 105 ke aas-paas hai. Lekin company par koi debt nahi hai aur inka financial growth bhi consistent hai. Pichle 3-5 saalon mein profit 19.4% se 23.40% CAGR tak grow hua hai, revenue 28.67% badha hai, aur Return on Capital Employed (ROCE) bhi 26.58% jaisa strong hai.

Future ka scene?

India ka oncology market bahut tezi se badh raha hai, aur stomach cancer ka market bhi 2030 tak USD 686.5 million tak pahunch sakta hai. Imfinzi ka approval AstraZeneca India ko is badhti hui market mein ek achha share dilwa sakta hai, khaas kar jab immunotherapy cancer treatments mein sabse zyada grow kar rahi hai. History mein bhi dekha gaya hai ki aise regulatory approvals ke baad stock mein aage bhi achhi tezi aati hai.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.